东阿县以"非遗+"模式推动文旅深度融合，构建中国阿胶博物馆、中国毛驴博物馆、毛驴乐园、阿胶世 界体验工厂、东阿阿胶城"三园两馆"文旅体系。数据显示，2025年东阿中医药文化旅游区接待游客达 107万人次，营业收入超1亿元。 东阿县委常委、宣传部部长王辉表示，当地立足非遗资源优势，依托冬至阿胶滋补节等节会，创新表达 形式、丰富体验场景，让非遗从陈列展品变为可看、可玩、可体验的生活元素，让群众在参与中感受文 化温度、共享发展成果。（经济日报记者 王金虎） 结绳花编、秸秆扎刻、面塑等非遗技艺集中亮相，匠人们指尖翻飞，一件件精巧作品跃然眼前。面塑艺 人任玉霞现场创作骏马造型面塑，为马年新春增添吉祥意趣，引得孩子们驻足欢呼。 作为大集亮点，阿胶定制摊位将国家级非物质文化遗产——东阿阿胶制作技艺与个性化定制深度融 合。"游客可按需定制专属阿胶礼盒，让非遗技艺可感可及、走进日常。"东阿阿胶文旅事业部总经理张 庆伟介绍，阿胶定制让古老技艺从工坊走向大众，在互动体验中彰显中医药文化魅力。 非遗走进日常生活，激活了青年人群的消费热情。"把艾灸贴在穴位上，过十几分钟，自主燃尽后就可 以拿掉……"东艾仙草负责人刘霞的摊位前，不少游客 ...

一街一巷藏文脉，一景一物蕴年味。在新春的热闹氛围里，经济日报记者走进大江南北的古街老巷，看 他们打破传统模样，以多元新潮的玩法解锁文旅新体验，既留住了烟火气与文化味，又激活了消费市场 与文旅产业，让老街区适配新消费、老传统对接新潮流。 昼赶市集夜赏灯 新春的脚步踏响古邑大街，浓浓的年味漫溢慈城小巷。近日，记者来到位于浙江省宁波市江北区慈城镇 的慈城古县城，这里白天游人如织、熙熙攘攘，夜幕降临后古城墙缀满星火，非遗花灯绽放光亮，昼夜 皆欢的盛景，让这座千年古城成为新春文旅的热门打卡地。 沿巷而行，"文运之路"灯组依次点亮，一步一景、一灯一故事，将文脉底蕴与新春喜庆紧密相连。"金 榜题名"灯组前，鎏金灯光熠熠生辉，金色鳌鱼昂首挺立，复刻着古城的鼎甲荣光；"鱼跃龙门"灯组 旁，碧波般的灯光轻轻晃动，锦鲤摆尾、海浪翻涌，龙门巍峨矗立；慈湖岸边的"踏浪琼林"灯组与湖光 山色交相辉映，搭配马年专属"骢马"意象，随水波轻轻晃动，如梦似幻，成为游人打卡留念的热门点 位。 "我们以灯为桥、以集为媒，让千年文脉走出古籍、融入生活，在传递新春福气的同时，把文气转化为 人气、商气。"慈城古县城旅游发展有限公司副总经理杨林波介绍，灯会 ...

春节期间，山东聊城市东阿中医药文化旅游区内人头攒动、暖意融融，"非遗年货大集"红红火火，游客 们看花灯、赏非遗、品美食、买年货，沉浸式体验传统年味。 古城街巷间，非遗展演轮番登场、好戏连台。西城门外，醒狮腾挪跳跃、气势昂扬，鼓舞展演鼓点铿 锵、气势如虹，将新春喜庆氛围推向高潮。集市上，熟食、海鲜琳琅满目，驴肉包、糕点香气四溢，各 类年货一应俱全。"这里既有地道美食，又能亲手制作阿胶糕、山楂丸，文化味和参与感都特别强。"带 着家人逛集的市民王琦说。 作为大集亮点，阿胶定制摊位将国家级非物质文化遗产——东阿阿胶制作技艺与个性化定制深度融 合。"游客可按需定制专属阿胶礼盒，让非遗技艺可感可及、走进日常。"东阿阿胶文旅事业部总经理张 庆伟介绍，阿胶定制让古老技艺从工坊走向大众，在互动体验中彰显中医药文化魅力。 非遗走进日常生活，激活了青年人群的消费热情。"把艾灸贴在穴位上，过十几分钟，自主燃尽后就可 以拿掉……"东艾仙草负责人刘霞的摊位前，不少游客在工作人员指导下通过艾灸温经通络、祛湿散 寒。不远处，游客正体验专业医师提供的号脉、推拿等康养服务；年轻游客们身着汉服漫步古城，衣袂 飘飘间，仿佛穿越千年，在青砖黛瓦间，邂 ...

Core Viewpoint - The acquisition and evolution of the direct selling license by Dong'e Ejiao reflect not only the strategic choices of a single enterprise but also the profound changes in the industry from institutional arbitrage to value return over the past decade [1]. Group 1: Institutional Foundation - The issuance of the direct selling management regulations in 2005 marked the beginning of the legal framework for the direct selling industry in China, distinguishing between legal direct selling and illegal pyramid schemes [3]. - Dong'e Ejiao's direct selling license approval in 2015 occurred during a critical transition period for the industry, characterized by a shift from chaotic growth to regulated operations [3]. - The rigorous qualification process for obtaining a direct selling license underscores its significance as a testament to a company's brand reputation, product quality, and management system [3]. Group 2: Strategic Choices - Dong'e Ejiao entered the direct selling sector due to its need to diversify sales channels, as it faced a decline in revenue from traditional distribution methods [6]. - The direct selling model aligns well with the characteristics of Dong'e Ejiao's products, which require in-depth explanation and have clear repurchase cycles, making it suitable for face-to-face health consultations [6]. - The direct selling approach allows Dong'e Ejiao to enhance profitability while providing consumers with more accessible pricing, thus creating a win-win situation [6]. Group 3: Endowment Support - Dong'e Ejiao's unique brand heritage and ongoing technological innovation are key factors that enable its success in the direct selling arena [7]. - The company has established significant assets, including a national engineering research center and participation in the formulation of national pharmacopoeia standards, which bolster its confidence in entering the direct selling market [7]. - Dong'e Ejiao's strategic shift towards technology-driven growth has led to increased R&D investment, reaching 210 million yuan in 2024, a 27.63% increase year-on-year [7]. Group 4: Industry Changes - Over the past decade, the direct selling industry in China has transitioned from a focus on license acquisition to a more rational return to the essence of the industry [11]. - The industry has seen a decline in growth rates, with 13 licensed companies suspending or abandoning their direct selling operations between 2023 and 2024 [11]. - The future of direct selling is expected to evolve into a model centered on technology empowerment and community interaction, emphasizing the importance of creating irreplaceable customer value [11]. Group 5: Rational Examination - Despite obtaining the direct selling license, Dong'e Ejiao has not rapidly expanded its direct selling business, reflecting a cautious approach influenced by various external factors [14]. - The company recognizes the dual-edged nature of the direct selling model and has chosen to prioritize brand reputation over immediate sales growth [14]. - The strategic value of the direct selling license lies in its potential to facilitate deeper consumer engagement and future business innovations, particularly in the context of increasing health awareness [15]. Conclusion - The ten-year journey of Dong'e Ejiao's direct selling license represents a significant period of maturation for the Chinese direct selling industry and highlights the balance between institutional benefits and corporate endowments [17]. - The direct selling license serves as a baseline for compliant operations, a testament to brand credibility, and a reflection of the industry's return to value [17].

Group 1 - On February 15, 2026, Shandong Province's key monitored tourist attractions received 1.666 million visitors and generated revenue of 92.82 million yuan [1] - Various cultural and folk activities were organized, including intangible cultural heritage experiences and traditional lantern festivals, enhancing the festive atmosphere [1] - The integration of traditional customs with modern celebrations has become a mainstream experience during the holiday [1] Group 2 - Multiple tourist attractions in Linyi and Jining launched themed events and activities, such as the "Cultural Jining" lantern festival, which combines traditional lantern art with modern technology [2] - The tourism market's consumption potential was effectively released through policies like ticket discounts and hotel promotions, stimulating market vitality [2] - The "Five Blessings" consumption season in Zaozhuang was strategically planned to enhance local tourism activities [2] Group 3 - Over 30 scenic spots in Yantai offered free or discounted entry, while hotels provided special winter packages and dining options to attract visitors [3] - The winter tourism sector, including ice and snow activities, has shown significant growth, with various events and experiences being organized across the province [5] - The integration of wellness and cultural experiences, such as hot spring and cultural tourism packages, has emerged as a new trend [5] Group 4 - Public cultural venues across the province saw increased attendance, with many offering free access and diverse activities, promoting cultural engagement during the holiday [6] - Various cultural events, including exhibitions and interactive experiences, were organized to enhance community participation and cultural appreciation [7] - The market for cultural and tourism integration is thriving, with innovative experiences and improved product offerings attracting visitors [8]

证券日报网讯2月13日，东阿阿胶（000423）在互动平台回答投资者提问时表示，截至2026年2月10日， 公司股东总数为71307户。 ...

Core Insights - The article discusses the shift in consumer behavior from traditional search methods to conversational AI interactions, highlighting a growing "invisible anxiety" among brands as they adapt to this change [1][2]. Group 1: Consumer Behavior Changes - Consumers are increasingly using conversational queries when seeking product recommendations, which reflects a significant change in search behavior [2][3]. - Real user inquiries are more complex and nuanced, often involving multiple variables such as demographics, health conditions, budget, and preferences [4][6]. - Over 80% of user questions are "combination punches," incorporating at least two complex variables, while AI-generated keyword expansions only cover about 50% of this complexity [5][4]. Group 2: Interaction Dynamics - Real conversations involve multiple rounds of questioning, with 45% of users engaging in two or more follow-up questions, revealing deeper needs and leading to more informed decisions [11][13]. - The nature of the questions posed significantly influences the AI's responses and the visibility of brands in search results [14][16]. Group 3: Source of Information - Different AI models exhibit varying preferences for information sources based on the specificity of user questions, with more detailed inquiries leading to references from local and commercial sources [18][20]. - The analysis of brand visibility shows that user-generated questions lead to a greater emphasis on lifestyle and purchasing guidance, while generic queries rely more on health information [18][20]. Group 4: Strategic Implications - The findings suggest a need for brands to adapt their marketing strategies to focus on human-centric approaches, leveraging the detailed insights from real user inquiries to enhance AI learning [22][23]. - Brands must ensure their marketing efforts align with the nuanced needs of consumers to effectively compete in the AI-driven landscape [22][23].

Group 1 - Xinda Biopharmaceutical announced a strategic collaboration with Eli Lilly to advance global R&D of innovative drugs in oncology and immunology, with a total potential value of up to $88.5 billion [1] - Under the agreement, Xinda will receive an upfront payment of $350 million and may earn up to approximately $8.5 billion in milestone payments related to R&D, regulatory, and commercialization achievements [1] - Xinda retains all rights for the projects in Greater China, while Eli Lilly obtains exclusive development and commercialization rights outside this region [1] Group 2 - Kangtai Biological announced the termination of its collaboration with AstraZeneca to establish a joint venture in the vaccine sector, which was initially planned to be set up in Beijing with a registered capital of approximately 345 million yuan (about $50 million) [2] - The decision to terminate was made due to significant market changes and increased investment risks in the vaccine industry, with no adverse impact on Kangtai's operations [2] Group 3 - China Resources Pharmaceutical announced plans to sell approximately 17.87% of its stake in Tianmai Biotechnology for a base price of about 1.42 billion yuan [3] - The sale will be conducted through a public listing, and as of the announcement date, China Resources holds less than 30% of Tianmai's shares [3] Group 4 - Dong'e Ejiao plans to invest 1.485 billion yuan to construct a health consumer goods industrial park, with a construction period of approximately 22 months [4] - The project aims to support the high-quality development of the health consumer goods business, including the production of food and health products [4] Group 5 - WuXi Biologics expects a revenue increase of approximately 16.7% to 21.79 billion yuan for the fiscal year ending December 31, 2025, with a projected profit growth of 45.3% to 5.733 billion yuan [5] - The growth is attributed to successful execution of its "Follow and Win" strategy, expansion of service offerings, and increased utilization of production capacity [7] Group 6 - Kintor Pharmaceutical signed a strategic cooperation agreement to expand its CAR-T cell therapy production base in Shanghai, with a total investment of up to 370 million yuan [8] - This initiative aligns with the commercialization of multiple CAR-T products and aims to enhance production capacity to support global competitiveness [8]

Group 1 - The core viewpoint of the news highlights the performance of the China Securities Pharmaceutical and Medical Device Innovation Index, with Zhejiang Medicine leading the gains at 1.43% and Xinhecheng experiencing the largest decline [1] - The Medical Innovation ETF (516820) has a latest price of 0.36 yuan, with a turnover rate of 0.28% and a transaction volume of 5.138 million yuan during the trading session [1] - Over the past month, the average daily transaction volume of the Medical Innovation ETF reached 62.8359 million yuan, indicating strong market interest [1] Group 2 - Recently, Eli Lilly's drug, Migalastat, received approval from the National Medical Products Administration of China for two formulations to treat moderate to severe active Crohn's disease and ulcerative colitis, marking a significant advancement in targeted therapies for autoimmune diseases in the digestive system [1] - According to CMB International, the pharmaceutical industry is experiencing structural differentiation due to medical insurance cost control and normalized centralized procurement, with resources increasingly concentrating on innovative pharmaceutical and medical device companies with technological barriers [1] - Since Q4 2025, both domestic and foreign institutions have been increasing their positions in the innovative pharmaceutical and medical device supply chain, reflecting a clearer market logic for allocating innovative assets with clinical value and overseas potential [1] Group 3 - The China Securities Pharmaceutical and Medical Device Innovation Index (931484) selects 30 publicly listed companies with good profitability, growth potential, and research innovation capabilities to reflect the overall performance of the pharmaceutical and medical device sector [2] - As of January 30, 2026, the top ten weighted stocks in the index include WuXi AppTec, Mindray Medical, Heng Rui Medicine, Aier Eye Hospital, and others, accounting for a total of 63.9% of the index [2]

Core Viewpoint - Dong-E E-Jiao is investing 1.485 billion yuan to build a health consumer goods industrial park, supporting its "1238" development strategy aimed at enhancing its dual business model of pharmaceuticals and health consumer products [1][2][3] Group 1: Investment and Strategic Development - The company plans to invest 1.485 billion yuan, with 1.421 billion yuan allocated for fixed assets and 0.64 billion yuan for working capital, to establish a health consumer goods industrial park [2] - The project will focus on the production of health consumer products, including food and health supplements, and will include facilities for quality inspection, e-commerce sorting, and storage [2][3] - The construction site is located in the Economic Development Zone of Dong'e County, Shandong Province, covering an area of 406,800 square meters, with a planned construction period of approximately 22 months [2][3] Group 2: Financial Performance and Shareholder Returns - Dong-E E-Jiao has shown consistent growth in revenue and net profit from 2020 to 2024, with revenue increasing from 3.409 billion yuan in 2020 to 5.921 billion yuan in 2024, and net profit rising from 0.43 billion yuan to 1.557 billion yuan during the same period [4][5] - The company has maintained a high dividend payout ratio, distributing a total of 4.081 billion yuan in dividends over five years, which exceeds its net profit during that period [6][7] - In the first three quarters of 2025, the company reported revenue of 4.766 billion yuan and a net profit of 1.274 billion yuan, reflecting a year-on-year growth of 4.41% and 10.53%, respectively [5][6]